RRSP02 The state of Life Sciences, pt 2 - How AI relates to human life and longevity with Dr. Ale...

Life sciences are at a critical inflection point, where scientific innovation, regulatory demands, and patient expectations converge with advances in data and artificial intelligence, positioning IT as a central driver of faster and more effective drug discovery and clinical development. This week, Dave and Rob continue with part 2 off the Life Sciences mini-series with Dr. Alex Zhavoronkov founder and CEO of Insilico Medicine to exploring how drug discovery and clinical development can become faster and more effective, and the role of AI in that process.    TLDR 00:40 – Introduction 01:00 – Hang out: Kill Bill Vol. 1 & 2 03:07 – Dig in: Life Sciences mini-series, Part 2 06:43 – Conversation with Dr Alex Zhavoronkov 42:12 – The future of AI in drug discovery and a new paradigm for pharma   Guest Dr. Alex Zhavoronkov: https://www.linkedin.com/in/zhavoronkov/   Hosts Dave Chapman:  https://www.linkedin.com/in/chapmandr/ Esmee van de Giessen:  https://www.linkedin.com/in/esmeevandegiessen/ Rob Kernahan:  https://www.linkedin.com/in/rob-kernahan/   Production Marcel van der Burg:  https://www.linkedin.com/in/marcel-vd-burg/ Dave Chapman:  https://www.linkedin.com/in/chapmandr/   Sound Ben Corbett:  https://www.linkedin.com/in/ben-corbett-3b6a11135/ Louis Corbett:   https://www.linkedin.com/in/louis-corbett-087250264/   'Realities Remixed' is an original podcast from Capgemini